Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1NET 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 147Breast Neoplasms 108Lung Neoplasms 93Carcinoma, Non-Small-Cell Lung 78Neoplasm Metastasis 68Glioblastoma 68Brain Neoplasms 65Glioma 59Pancreatic Neoplasms 46Carcinoma, Renal Cell 43Multiple Myeloma 41Squamous Cell Carcinoma of Head and Neck 39Colorectal Neoplasms 39Lymphoma, Large B-Cell, Diffuse 37Neoplasms 34Melanoma 33Lymphoma 32Carcinoma, Hepatocellular 32Urinary Bladder Neoplasms 31Ovarian Neoplasms 29Astrocytoma 28Sarcoma 25Oropharyngeal Neoplasms 24Lymphoma, Follicular 23Central Nervous System Neoplasms 23Rectal Neoplasms 22Uterine Cervical Neoplasms 21Triple Negative Breast Neoplasms 21Mouth Neoplasms 21Lymphoma, Non-Hodgkin 21

Interventions

Carboplatin 12Paclitaxel 11Gemcitabine 11Capecitabine 7Irinotecan 6Fluorouracil 5Cisplatin 5Radiotherapy 4Oxaliplatin 4Leucovorin 4Bevacizumab 4pembrolizumab 3Filgrastim 3Etoposide 3Erlotinib Hydrochloride 3Cyclophosphamide 3etoposide phosphate 2atezolizumab 2Trastuzumab 2Topotecan 2Taxes 2Surveys and Questionnaires 2Peripheral Blood Stem Cell Transplantation 2Magnetic Resonance Spectroscopy 2Genetic Testing 2FAPI-46 2Docetaxel 2CP protocol 2Amifostine 2Albumin-Bound Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Unknown Primary × Magnetic Resonance Spectroscopy × Clear all
NCT04459273 2026-02-05

FAPI PET RDRC

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
26 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasm

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Unknown Primary, Skin Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Hematologic Neoplasms

NCT00119314 2015-05-27

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡